You are here

Victoza

Teva launches generic version of Novo Nordisk's diabetes drug Victoza

Reuters

Mon, 06/24/24 - 10:12 pm

Teva Pharmaceutical

type 2 diabetes

3 patent expirations in 2024 and how companies are pivoting

Pharma Voice

Wed, 04/17/24 - 11:13 am

GLP-1s Like Novo Nordisk’s Ozempic Do Not Increase Thyroid Cancer Risk: Study

BioSpace

Wed, 04/10/24 - 09:48 am

EMA to Review Diabetes and Weight-Loss Drugs for Suicidal Ideation Risk

BioSpace

Tue, 04/9/24 - 11:11 am

Many patients keep weight off after stopping anti-obesity meds: study

Axios

Wed, 01/24/24 - 10:44 am

Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

Fierce Pharma

Wed, 03/23/22 - 10:38 am

The top 15 blockbuster patent expirations coming this decade

Fierce Pharma

Mon, 07/12/21 - 11:08 am

Novo Nordisk scraps Type 1 diabetes drug after phase 2 trial

Fierce Biotech

Fri, 10/30/20 - 10:16 am

clinical trials

type 1 diabetes

Mylan, seeking to market Victoza generic, convinces panel to start up patent review

Fierce Pharma

Wed, 06/24/20 - 11:18 pm

How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes

Fierce Biotech

Thu, 02/13/20 - 10:44 am

Novo Nordisk’s quiet entry into the year of Alzheimer’s

EP Vantage

Mon, 01/20/20 - 10:19 pm

Alzheimer's disease

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Fri, 09/27/19 - 09:10 am

EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

Fierce Pharma

Tue, 09/17/19 - 03:41 pm

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

BioSpace

Thu, 08/22/19 - 05:01 pm

Novo Nordisk’s Victoza gets FDA okay for pediatric use

Pharmaforum

Tue, 06/18/19 - 10:10 am

type 2 diabetes

Novo seeks Victoza label expansion with fresh pediatric trial results

Biopharma Dive

Mon, 04/29/19 - 09:33 pm

type 2 diabetes

Novo Nordisk settles US patent litigation case on Victoza (liraglutide) with Teva

Pharmaceutical Business Review

Wed, 03/20/19 - 12:16 pm

Teva Pharmaceutical

Novo's Victoza won't face Teva copies until 2023. Can semaglutide fill the gap by then?

Fierce Pharma

Mon, 03/18/19 - 05:05 pm

Teva Pharmaceutical

Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease

Fierce Biotech

Tue, 07/24/18 - 10:32 am

Parkinson's Disease

ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Fierce Pharma

Mon, 06/25/18 - 09:07 pm

Pages